• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer.抗凋亡蛋白生存素衍生肽疫苗用于晚期或复发性尿路上皮癌患者的I期临床研究。
Cancer Immunol Immunother. 2009 Nov;58(11):1801-7. doi: 10.1007/s00262-009-0691-x. Epub 2009 Mar 18.
2
Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.抗凋亡蛋白survivin衍生肽疫苗联合或不联合α干扰素治疗晚期或复发性尿路上皮癌患者的潜在生存获益——Ⅰ期临床试验结果
Clin Dev Immunol. 2013;2013:262967. doi: 10.1155/2013/262967. Epub 2013 Nov 20.
3
Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.Ⅰ型干扰素增强和抗凋亡蛋白 survivin 衍生肽疫苗的临床疗效在晚期结直肠癌患者中的作用。
Cancer Sci. 2011 Jun;102(6):1181-7. doi: 10.1111/j.1349-7006.2011.01918.x. Epub 2011 Apr 24.
4
Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Survivin 肽疫苗治疗晚期或复发性口腔癌患者的 I 期临床试验。
Cancer Sci. 2011 Feb;102(2):324-9. doi: 10.1111/j.1349-7006.2010.01789.x. Epub 2010 Dec 10.
5
Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.口腔癌患者中源自生存素及其剪接变体生存素-2B的HLA-A24限制性细胞毒性T细胞表位之间免疫原性的比较研究
J Transl Med. 2009 Jan 6;7:1. doi: 10.1186/1479-5876-7-1.
6
A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.一种靶向凋亡抑制蛋白survivin的强效免疫原性通用癌症疫苗。
Clin Cancer Res. 2005 Feb 15;11(4):1474-82. doi: 10.1158/1078-0432.CCR-03-0817.
7
An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.一种肿瘤相关蛋白survivin的HLA - A24限制性细胞毒性T淋巴细胞表位。
Clin Cancer Res. 2002 Jun;8(6):1731-9.
8
Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.α-干扰素（IFNα）在生存素 2B 衍生肽疫苗接种治疗晚期胰腺癌患者中的免疫治疗益处。
Cancer Sci. 2013 Jan;104(1):124-9. doi: 10.1111/cas.12046. Epub 2012 Dec 16.
9
[Anti-apoptosis protein, survivin-2B-derived peptide vaccine therapy].[抗凋亡蛋白，生存素-2B衍生肽疫苗疗法]
Gan To Kagaku Ryoho. 2004 Oct;31(11):1634-6.
10
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.抗凋亡蛋白生存素衍生肽疫苗用于晚期或复发性乳腺癌患者的I期临床研究的临床及免疫学评估
J Transl Med. 2008 May 10;6:24. doi: 10.1186/1479-5876-6-24.

引用本文的文献

1
Vaccine approaches to treat urothelial cancer.用于治疗尿路上皮癌的疫苗方法。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2379086. doi: 10.1080/21645515.2024.2379086. Epub 2024 Jul 23.
2
Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications.Survivin 表达在腔面型乳腺癌及其相邻正常组织中的表达对于免疫肿瘤学的应用。
Int J Mol Sci. 2023 Jul 23;24(14):11827. doi: 10.3390/ijms241411827.
3
Prostate cancer autoantibodies - applications in diagnosis, prognosis, monitoring disease progression and immunotherapy.前列腺癌自身抗体——在诊断、预后、监测疾病进展及免疫治疗中的应用
Am J Clin Exp Urol. 2023 Apr 15;11(2):79-102. eCollection 2023.
4
Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study.Survivin（BIRC5）肽疫苗在4T1小鼠乳腺肿瘤模型中的应用：三阴性乳腺癌潜在的新辅助T细胞免疫疗法：一项初步研究
Vaccines (Basel). 2023 Mar 13;11(3):644. doi: 10.3390/vaccines11030644.
5
Exploring the role of survivin in neuroendocrine neoplasms.探讨生存素在神经内分泌肿瘤中的作用。
Oncotarget. 2020 Jun 9;11(23):2246-2258. doi: 10.18632/oncotarget.27631.
6
Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?以生存素 BIRC5 为靶点的癌症治疗学：在研究了二十多年之后，我们还能做些什么？
J Exp Clin Cancer Res. 2019 Aug 22;38(1):368. doi: 10.1186/s13046-019-1362-1.
7
Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy series.接种 survivin 2B 肽后胰腺癌的免疫组织化学分析：尸检系列分析。
Cancer Sci. 2019 Aug;110(8):2386-2395. doi: 10.1111/cas.14099. Epub 2019 Jul 11.
8
High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4 and CD8 T-Cell Epitopes.一种含有CD4和CD8 T细胞表位的新型生存素LSP癌症疫苗具有高治疗效果。
Front Oncol. 2018 Nov 13;8:517. doi: 10.3389/fonc.2018.00517. eCollection 2018.
9
Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.基于生存素的鳞状细胞癌治疗策略。
Int J Mol Sci. 2018 Mar 24;19(4):971. doi: 10.3390/ijms19040971.
10
Survivin: a unique target for tumor therapy.生存素：肿瘤治疗的独特靶点。
Cancer Cell Int. 2016 Jun 23;16:49. doi: 10.1186/s12935-016-0326-1. eCollection 2016.

本文引用的文献

1
Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96.抗原特异性T淋巴细胞的表型分析。《科学》。1996年。第274卷：94 - 96页。
J Immunol. 2011 Jul 1;187(1):7-9.
2
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.抗凋亡蛋白生存素衍生肽疫苗用于晚期或复发性乳腺癌患者的I期临床研究的临床及免疫学评估
J Transl Med. 2008 May 10;6:24. doi: 10.1186/1479-5876-6-24.
3
TLR9 as a key receptor for the recognition of DNA.TLR9作为识别DNA的关键受体。
Adv Drug Deliv Rev. 2008 Apr 29;60(7):795-804. doi: 10.1016/j.addr.2007.12.004. Epub 2008 Jan 3.
4
Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway.热休克蛋白90-肽复合物负载的树突状细胞通过内体途径进行高效交叉呈递。
J Immunol. 2007 Aug 1;179(3):1803-13. doi: 10.4049/jimmunol.179.3.1803.
5
Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant.在不完全弗氏佐剂中使用三种不同临床/实验室技术乳化基于肽的疫苗的免疫学后果。
J Transl Med. 2006 Oct 23;4:42. doi: 10.1186/1479-5876-4-42.
6
Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy.凋亡抑制蛋白家族成员survivin在膀胱癌中的表达及抗原性：对特异性免疫治疗的意义
Urology. 2006 May;67(5):955-9. doi: 10.1016/j.urology.2005.11.052. Epub 2006 Apr 25.
7
The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.细胞因子基因共转导对使用表达肿瘤相关抗原的基因修饰树突状细胞进行癌症疫苗治疗的增强作用。
Int J Oncol. 2006 Apr;28(4):947-53.
8
Characterization of monocyte-derived dendritic cells maturated with IFN-alpha.用干扰素-α 成熟的单核细胞衍生树突状细胞的特征分析
Scand J Immunol. 2006 Mar;63(3):217-22. doi: 10.1111/j.1365-3083.2006.01728.x.
9
A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.一种靶向凋亡抑制蛋白survivin的强效免疫原性通用癌症疫苗。
Clin Cancer Res. 2005 Feb 15;11(4):1474-82. doi: 10.1158/1078-0432.CCR-03-0817.
10
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer.抗凋亡蛋白、生存素衍生肽疫苗治疗晚期或复发性结直肠癌患者的I期临床研究。
J Transl Med. 2004 Jun 13;2(1):19. doi: 10.1186/1479-5876-2-19.

抗凋亡蛋白生存素衍生肽疫苗用于晚期或复发性尿路上皮癌患者的I期临床研究。

Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer.

作者信息

Honma Ichiya, Kitamura Hiroshi, Torigoe Toshihiko, Takahashi Akari, Tanaka Toshiaki, Sato Eiji, Hirohashi Yoshihiko, Masumori Naoya, Tsukamoto Taiji, Sato Noriyuki

机构信息

Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.

出版信息

Cancer Immunol Immunother. 2009 Nov;58(11):1801-7. doi: 10.1007/s00262-009-0691-x. Epub 2009 Mar 18.

DOI:10.1007/s00262-009-0691-x
PMID:19294381
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11030772/
Abstract

Survivin, a member of the inhibitor of apoptosis protein family, is expressed in many malignant tumors including urothelial cancer but is hardly detectable in normal, differentiated adult tissues. Previously we reported CD8-positive cytotoxic T-lymphocytes (CTLs) were successfully induced by stimulation with survivin-2B80-88 peptide in vitro. We started a phase I clinical study of survivin-2B80-88 peptide vaccination for advanced urothelial cancer patients to assess the safety and efficacy of this vaccination. Nine patients were received vaccination and were evaluated for immunological evaluation, adverse events, and clinical responses. A total of 46 vaccinations were carried out. There was no severe adverse event. HLA-A24/survivin-2B80-88 peptide tetramer analysis revealed a significant increase in the peptide-specific CTL frequency after the vaccination in five patients. Slight reduction of the tumor volume was observed in one patient. Survivin-2B80-88 peptide-based vaccination is safe and should be further considered for potential immune and clinical efficacy in urothelial cancer patients.

摘要

生存素是凋亡抑制蛋白家族的成员之一，在包括尿路上皮癌在内的许多恶性肿瘤中表达，但在正常的、分化成熟的成人组织中几乎检测不到。此前我们报道，在体外使用生存素-2B80-88肽刺激可成功诱导CD8阳性细胞毒性T淋巴细胞（CTL）。我们启动了一项针对晚期尿路上皮癌患者的生存素-2B80-88肽疫苗接种的I期临床研究，以评估该疫苗接种的安全性和有效性。9名患者接受了疫苗接种，并进行了免疫学评估、不良事件和临床反应评估。共进行了46次疫苗接种。未出现严重不良事件。HLA-A24/生存素-2B80-88肽四聚体分析显示，5名患者接种疫苗后，肽特异性CTL频率显著增加。1名患者的肿瘤体积略有减小。基于生存素-2B80-88肽的疫苗接种是安全的，应进一步考虑其在尿路上皮癌患者中的潜在免疫和临床疗效。